Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Faculty Opinions recommendation of Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726145666.793525559 ◽

2016 ◽

Author(s):

Daniel Vorobiof

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment

10.1158/0008-5472.sabcs10-p6-14-05 ◽

2010 ◽

Author(s):

G von Minckwitz ◽

K Schwedler ◽

M Schmidt ◽

J Barinoff ◽

C Mundhenke ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Trastuzumab Treatment ◽

Phase Iii Study ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial

10.1158/1538-7445.sabcs20-pd3-03 ◽

2021 ◽

Author(s):

Frankie Ann Holmes ◽

Beverly Moy ◽

Suzette Delaloge ◽

Stephen Chia ◽

Bent Ejlertsen ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Her2 Positive ◽

Phase 3 ◽

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

10.1158/0008-5472.sabcs12-p5-18-26 ◽

2012 ◽

Cited By ~ 5

Author(s):

SM Swain ◽

S-B Kim ◽

J Cortes ◽

J Ro ◽

V Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70130-x ◽

2013 ◽

Vol 14 (6) ◽

pp. 461-471 ◽

Cited By ~ 553

Author(s):

Sandra M Swain ◽

Sung-Bae Kim ◽

Javier Cortés ◽

Jungsil Ro ◽

Vladimir Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2011.06.021 ◽

2011 ◽

Vol 47 (15) ◽

pp. 2273-2281 ◽

Cited By ~ 98

Author(s):

Gunter von Minckwitz ◽

Kathrin Schwedler ◽

Marcus Schmidt ◽

Jana Barinoff ◽

Christoph Mundhenke ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study ◽

Overall Survival Analysis ◽

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00551-3 ◽

2016 ◽

Vol 17 (3) ◽

pp. 367-377 ◽

Cited By ~ 249

Author(s):

Arlene Chan ◽

Suzette Delaloge ◽

Frankie A Holmes ◽

Beverly Moy ◽

Hiroji Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30717-9 ◽

2017 ◽

Vol 18 (12) ◽

pp. 1688-1700 ◽

Cited By ~ 212

Author(s):

Miguel Martin ◽

Frankie A Holmes ◽

Bent Ejlertsen ◽

Suzette Delaloge ◽

Beverly Moy ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽